We are live on ! Find out more
ACM

Altium Capital Management Portfolio holdings

AUM $47.5M
1-Year Est. Return 115.72%
This Fund
S&P 500
This Quarter Est. Return
+7.84%
1 Year Est. Return
+115.72%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$245M
AUM Growth
-$7.55M
Cap. Flow
+$30.4M
Cap. Flow %
12.39%
Top 10 Hldgs %
55.89%
Holding
90
New
18
Increased
14
Reduced
12
Closed
22

Top Buys

Rank Stock Value
1
SKYE icon
Skye Bioscience
SKYE
+$16M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$10.5M
3
ARGX icon
argenx
ARGX
+$8.8M
4
CTNM
Contineum Therapeutics
CTNM
+$6.91M
5
RZLT icon
Rezolute
RZLT
+$5.84M

Top Sells

Rank Stock Value
1
BHVN icon
Biohaven
BHVN
+$7.66M
2
OLMA icon
Olema Pharmaceuticals
OLMA
+$6.85M
3
AXSM icon
Axsome Therapeutics
AXSM
+$6.52M
4
MIRM icon
Mirum Pharmaceuticals
MIRM
+$5.22M
5
NGNE icon
Neurogene
NGNE
+$5.09M

Sector Composition

Rank Sector Weight
1 Healthcare 96.66%
2 Consumer Discretionary 1.68%
3 Miscellaneous 1.62%
4 Technology 0.03%
5 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VERA icon
1
Vera Therapeutics
VERA
$2.53B
$25.8M 10.54%
714,000
+4,000
+0.6% +$159K
ADMA icon
2
ADMA Biologics
ADMA
$2.07B
$16.9M 6.89%
1,510,000
-30,000
-2% -$252K
XENE icon
3
Xenon Pharmaceuticals
XENE
$5.68B
$14.1M 5.74%
360,600
+12,600
+4% +$504K
ITCI
4
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$13.2M 5.39%
193,000
+80,000
+71% +$5.55M
SRPT icon
5
Sarepta Therapeutics
SRPT
$2.16B
$12.9M 5.28%
+81,900
New +$10.5M
INSM icon
6
Insmed
INSM
$28.3B
$12.7M 5.19%
190,000
+70,000
+58% +$2.71M
ALIM
7
DELISTED
Alimera Sciences
ALIM
$12M 4.88%
2,150,000
-400,000
-16% -$1.42M
SKYE icon
8
Skye Bioscience
SKYE
$9.03M
$10.8M 4.41%
+168,762
New +$16M
ARGX icon
9
argenx
ARGX
$61.6B
$9.89M 4.04%
+23,000
New +$8.8M
SLNO
10
DELISTED
Soleno Therapeutics
SLNO
$8.69M 3.54%
212,909
+60,000
+39% +$2.54M
AVDL
11
DELISTED
Avadel Pharmaceuticals
AVDL
$8.58M 3.5%
610,000
+56,943
+10% +$928K
CPRX
12
DELISTED
Catalyst Pharmaceutical
CPRX
$7.75M 3.16%
500,000
– –
CTNM
13
Contineum Therapeutics
CTNM
$558M
$7.56M 3.08%
+429,340
New +$6.91M
RZLT icon
14
Rezolute
RZLT
$406M
$7.31M 2.98%
+1,700,000
New +$5.84M
ASND icon
15
Ascendis Pharma A/S
ASND
$17.3B
$6.82M 2.78%
50,000
+25,000
+100% +$3.4M
VKTX icon
16
Viking Therapeutics
VKTX
$3.73B
$6.47M 2.64%
122,000
+37,000
+44% +$2.43M
SVRA icon
17
Savara
SVRA
$1.09B
$6.35M 2.59%
1,575,000
+240,000
+18% +$1.07M
ZVRA icon
18
Zevra Therapeutics
ZVRA
$713M
$5.7M 2.32%
1,162,416
+820,955
+240% +$3.89M
MLTX icon
19
MoonLake Immunotherapeutics
MLTX
$1.06B
$5.06M 2.06%
+115,000
New +$4.87M
LRMR icon
20
Larimar Therapeutics
LRMR
$407M
$5.02M 2.05%
693,000
-2,000
-0.3% -$15.3K
XTNT icon
21
Xtant Medical Holdings
XTNT
$48.5M
$4.67M 1.91%
7,415,413
-232,460
-3% -$185K
AXSM icon
22
Axsome Therapeutics
AXSM
$11.6B
$4.03M 1.64%
50,000
-88,000
-64% -$6.52M
REAL icon
23
The RealReal
REAL
$1.2B
$3.99M 1.63%
1,250,238
+450,238
+56% +$1.66M
HELP
24
Cybin Inc
HELP
$948M
$3.78M 1.54%
367,197
– –
OTLK icon
25
Outlook Therapeutics
OTLK
$161M
$3.7M 1.51%
+501,785
New +$4.03M
1
2 3 4

Similar funds

BAM
BTS Asset Management Lincoln, Massachusetts $47.4M AUM 1.28% 1-Year Est. Return
VI
Versor Investments New York $47.5M AUM 100.43% 1-Year Est. Return
JCM
JAT Capital Management Greenwich, Connecticut $47.4M AUM 177.04% 1-Year Est. Return
YEPX
Yorktown Energy Partners X New York $47.6M AUM 46.93% 1-Year Est. Return
OGC
One68 Global Capital New York $47.2M AUM 6.52% 1-Year Est. Return
MCM
M28 Capital Management Stamford, Connecticut $47.2M AUM 32.31% 1-Year Est. Return
BJB
Broadhurst Jeffrey B $47M AUM
NA
Novus Advisors Greenville, South Carolina $48M AUM 17.82% 1-Year Est. Return

Altium Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, Altium Capital Management held 90 positions worth $245M, down 3% from $253M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Altium Capital Management deployed $30.4M of net new capital in Q2 2024, opening 18 new positions and adding to 14 existing holdings. Its largest new stake was Skye Bioscience: 168,762 shares worth $10.8M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 87% a quarter earlier, followed by Consumer Discretionary and Miscellaneous.

On the sell side, the largest reduction was Axsome Therapeutics, an estimated $6.52M trimmed.

  • Altium Capital Management's largest Q2 2024 buy was Skye Bioscience: 168,762 shares worth $10.8M.
  • Altium Capital Management added most to Intra-Cellular Therapies Inc. in Q2 2024, an estimated $5.55M increase.
  • Altium Capital Management's biggest Q2 2024 reduction was Axsome Therapeutics, cutting an estimated $6.52M.
  • Altium Capital Management fully exited Biohaven in Q2 2024, selling an estimated $7.66M.
  • Altium Capital Management's ten largest holdings make up 56% of its $245M portfolio in Q2 2024.
  • Altium Capital Management opened 18 new positions and closed 22 in Q2 2024.
  • Altium Capital Management's portfolio value fell 3% quarter-over-quarter to $245M.

Based on Altium Capital Management's 13F filing for Q2 2024, filed 15 Aug 2024.